Latest Breaking News On - பெர்ரி நிறுவனம் பொது உறவுகள் - Page 7 : comparemela.com

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company’s common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 10,678,872 shares of the Company’s common stock, at a purchase price of $1.311 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about July 16,

New yorkUnited statesAdam daleyAshley robinsonExchange commissionLifesci advisorsAllena pharmaceuticals incBerry company public relationsAllena pharmaceuticalsHc wainwright coPrivate securities litigation reform actQuarterly reportSci advisorsபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்ஆடம் டேலி